Battelle and Canopy Growth Announce Strategic Collaboration to Advance Cannabis Research

Cannabis leader has completed four federally legal shipments of cannabis to the United States to pursue advanced R&D work with Battelle

COLUMBUS, OH and SMITHS FALLS, ON, Nov. 27, 2018 /CNW/ – Battelle, the world’s largest nonprofit research and development organization, and Canopy Growth Corporation (“Canopy Growth”) (TSX: WEED) (NYSE: CGC), the world’s largest diversified cannabis company, today announced the completion of multiple fully legal cannabis imports from Canada to the United States. Battelle and Canopy Growth will work together to advance knowledge surrounding cannabis in support of medical research and novel product development.

Canopy Growth and Battelle completed the rigorous federal approval process required to import cannabis products into the United States and since October 9th, the organizations have completed four product transfers to Battelle’s secure research facilities pursuant to United States Drug Enforcement Agency approvals. For decades, Battelle scientists have been developing methods for testing a variety of controlled substances as well as employing analytical chemistry services for government and private industry.

Notably, product transfers have consisted of a variety of cannabis form factors, including dried cannabis and Canopy Growth’s precisely dosed Softgel capsules.

As more states, including Ohio, approve the use of medical cannabis to help individuals with certain illnesses, we believe that Battelle will be able to apply our rigorous and independent research and analysis to advance knowledge and improve safety in what is essentially uncharted territory. We’re pleased to work with Canopy Growth, a respected global leader in this emerging market.

Lou Von Thaer, Battelle President and CEO

“We’re pleased to begin collaborating with a trusted institution of Battelle’s reputation,” said Mark Zekulin, President and Co-CEO of Canopy Growth. “This offers us a unique ability to advance standardization, intellectual property development and clinical research that can improve the understanding and legal application of cannabis and cannabinoids around the globe.”

With a DEA Schedule I Researcher License and product obtained from the National Institute on Drug Abuse drug supply program, that is fully legal at the local, state and federal level, Battelle is already conducting research and development studies involving human subjects and smoking behavior at an East Coast research center.

Additional areas of research will now begin in earnest to build a robust knowledge base surrounding Canopy Growth’s suite of cannabis products.

Here’s to Future Growth.

About Battelle

Every day, the people of Battelle apply science and technology to solving what matters most. At major technology centers and national laboratories around the world, Battelle conducts research and development, designs and manufactures products, and delivers critical services for government and commercial customers. Headquartered in Columbus, Ohio since its founding in 1929, Battelle serves the national security, health and life sciences, and energy and environmental industries. For more information, visit www.battelle.org.

About Canopy Growth Corporation

Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time. The Company has operations in 12 countries across five continents. The Company is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public’s understanding of cannabis, and through its partly owned subsidiary, Canopy Health Innovations has devoted millions of dollars toward cutting edge, commercializable research and IP development. Through partly owned subsidiary Canopy Rivers Corporation, the Company is providing resources and investment to new market entrants and building a portfolio of stable investments in the sector. From our historic public listing on the Toronto Stock Exchange and New York Stock Exchange to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth. Canopy Growth has established partnerships with leading sector names including cannabis icon Snoop Dogg, breeding legends DNA Genetics and Green House seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates ten licensed cannabis production sites with over 4.3 million square feet of production capacity, including over 500,000 square feet of GMP certified production space. For more information visit www.canopygrowth.com

Original press release

Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.

Published by NCV Newswire
NCV Newswire
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.

Get Our Sunday Newsletter